These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33105975)

  • 1. Editorial: thiopurine/anti-TNF use during pregnancy-more encouraging safety data. Authors' reply.
    Mertz Nørgård B; Friedman S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1411. PubMed ID: 33105975
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: thiopurine/anti-TNF use during pregnancy-more encouraging safety data.
    Chowdhury R; Kane S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1409-1410. PubMed ID: 33105977
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors' reply.
    Friedman AB; Sparrow MP
    Aliment Pharmacol Ther; 2018 Jul; 48(1):98-99. PubMed ID: 29882984
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
    Stobaugh DJ; Deepak P
    Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: can we get more clinical benefit from thiopurine metabolite testing? Authors' reply.
    Wong DR; Hooymans PM
    Aliment Pharmacol Ther; 2017 Mar; 45(6):858-859. PubMed ID: 28211625
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors' reply.
    Broekman MMTJ; Wanten GJ; de Jong DJ
    Aliment Pharmacol Ther; 2018 Jan; 47(1):130-131. PubMed ID: 29226420
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial: Are thiopurines and anti-TNFα agents safe to use in pregnant patients with inflammatory bowel disease?
    Sheibani S; Mahadevan U
    Am J Gastroenterol; 2013 Mar; 108(3):441-3. PubMed ID: 23459048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: anti-TNF therapy-a double-edged sword? Authors' reply.
    Korzenik J; Larsen MD; Nielsen J; Kjeldsen J; Nørgård BM
    Aliment Pharmacol Ther; 2019 Oct; 50(7):823-824. PubMed ID: 31532552
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors' reply.
    Lee HH; Bae JM; Lee BI
    Aliment Pharmacol Ther; 2018 Sep; 48(6):684-685. PubMed ID: 30132943
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
    Blesl A; Högenauer C; Borenich A; Berghold A; Wenzl H; Petritsch W
    Aliment Pharmacol Ther; 2021 Sep; 54(5):720-721. PubMed ID: 34379834
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications-authors' reply.
    Khan N; Lewis JD
    Aliment Pharmacol Ther; 2018 Feb; 47(3):448. PubMed ID: 29314125
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
    Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
    Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.
    Rundquist S; Sachs MC; Eriksson C; Olén O; Montgomery S; Halfvarson J
    Aliment Pharmacol Ther; 2021 Mar; 53(5):642-643. PubMed ID: 33566420
    [No Abstract]   [Full Text] [Related]  

  • 15. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
    Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
    Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
    Roblin X; Nancey S; Paul S
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1319-1320. PubMed ID: 34029416
    [No Abstract]   [Full Text] [Related]  

  • 17. Thiopurine therapy in inflammatory bowel disease.
    Ha C; Dassopoulos T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 May; 45(10):1372. PubMed ID: 28417494
    [No Abstract]   [Full Text] [Related]  

  • 19. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
    Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
    J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease.
    Cozijnsen MA; Escher JC; Griffiths A; Turner D; de Ridder L
    Inflamm Bowel Dis; 2015 Apr; 21(4):951-61. PubMed ID: 25723615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.